Other Health

Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference

Friday, February 26, 2021 - 10:00pm

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021 at 10:30 a.m.

Key Points: 
  • Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021 at 10:30 a.m.
  • Live audio webcast of the presentation will be accessible and available for replay from the Events & Presentations section of the Companys website at: http://investor.fiveprime.com/events.cfm .
  • Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
  • Five Prime collaborates with leading global pharmaceutical companies and has therapies in pre-clinical and clinical development.

Alpha Phi Alpha Fraternity, Inc.’s Project Alpha and Global AIDS Service Organization Extend Partnership to Address Rising STIs Among Black Youth

Friday, February 26, 2021 - 1:30pm

Each chapter will also coordinate with their respective Regional Project Alpha Chairman to present their findings at their respective regional conventions as well.

Key Points: 
  • Each chapter will also coordinate with their respective Regional Project Alpha Chairman to present their findings at their respective regional conventions as well.
  • Proper education can influence behaviors, including delaying the onset of sex, reducing sexual encounters, and becoming more selective of sexual partners.
  • Alpha Phi Alpha Fraternity, Inc., headquartered in Baltimore, MD, was founded on December 4, 1906, at Cornell University in Ithaca, NY.
  • For more information, visit: apa1906.net and follow Alpha Phi Alpha Fraternity, Inc. on Twitter and Instagram @apa1906network .

Octave Bioscience to Present New Analyses Addressing the Complex Unmet Needs of Multiple Sclerosis Through Quantitative and Image-Based Measurement of Multiple Pathways and Their Biomarkers at the ACTRIMS Forum 2021

Friday, February 26, 2021 - 12:30pm

The posters presented by Octave Bioscience at the ACTRIMS Forum 2021 underscore the companys commitment to the pursuit of revealing deeper clinical insights and addressing the multiple challenges and unmet needs associated with MS.

Key Points: 
  • The posters presented by Octave Bioscience at the ACTRIMS Forum 2021 underscore the companys commitment to the pursuit of revealing deeper clinical insights and addressing the multiple challenges and unmet needs associated with MS.
  • Current tools to evaluate and manage patients are often subjective, qualitative, and inadequate to address critical questions of interest.
  • Octave is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS.
  • Following are the five posters accepted to the ACTRIMS Forum 2021, which can be found here :

Amneal Receives Approval for Generic Version of Ortho Evra®

Friday, February 26, 2021 - 11:02am

In conjunction with its approval, Amneal received a Competitive Generic Therapy (CGT) designation by the FDA and has been granted 180 days of exclusivity.

Key Points: 
  • In conjunction with its approval, Amneal received a Competitive Generic Therapy (CGT) designation by the FDA and has been granted 180 days of exclusivity.
  • Amneals Norelgestromin and Ethinyl Estradiol Transdermal System is the generic version of the reference listed drug (RLD) Ortho Evra and will be marketed under the proprietary name Zafemy.
  • Todays approval is a significant milestone for patients and our company, said Chirag and Chintu Patel, Co-Chief Executive Officers.
  • Xulane is the only other equivalent to Ortho Evra currently available on the market.

European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older

Friday, February 26, 2021 - 11:45am

The epidemiology of pneumococcal serotypes causing disease has been changing due to the success of pneumococcal conjugate vaccines targeting pediatric and adult populations.

Key Points: 
  • The epidemiology of pneumococcal serotypes causing disease has been changing due to the success of pneumococcal conjugate vaccines targeting pediatric and adult populations.
  • In June 2020 Pfizer announced initiation of two Phase three trials for 20vPnC evaluating the safety and efficacy of the investigational vaccine in infants.
  • Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
  • Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.

Global Sepsis Diagnostics Market Analysis & Segment Forecast, 2020-2027 - Focus on Microbiology, Molecular Diagnostics, Biomarkers, Immunoassays, Flow Cytometry - ResearchAndMarkets.com

Friday, February 26, 2021 - 10:03am

Moreover, the favorable reimburse scenario in developed economies and burgeoning healthcare infrastructure in low and middle-income countries is expected to propel market growth.

Key Points: 
  • Moreover, the favorable reimburse scenario in developed economies and burgeoning healthcare infrastructure in low and middle-income countries is expected to propel market growth.
  • In terms of product, the market is segmented into instruments, blood culture media, assay kits and reagents, and software.
  • Based on technology, the market is further bifurcated into microbiology, molecular diagnostics, biomarkers, immunoassays, and flow cytometry.
  • However, the kits & reagents market segment is expected to witness fastest growth over the forecast period.

Global Syndromic Multiplex Diagnostic Market Growth, Trends, and Forecasts Report 2020-2025 - Respiratory Syndrome is Expected to Hold the Major Market Share - ResearchAndMarkets.com

Friday, February 26, 2021 - 8:35am

The "Syndromic Multiplex Diagnostic Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Syndromic Multiplex Diagnostic Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The syndromic multiplex diagnostic market is anticipated to grow with a CAGR of nearly 7.2% during the forecast period.
  • Respiratory syndromes account for the largest share of the syndromic multiplex diagnostics market and expected to continue the same throughout the forecast period.
  • The Global Syndromic multiplex diagnostic market is moderately competitive and consists of several major players.

Olympus Exercises Option to Buy Israeli Medical Device Company Medi-Tate to Drive Global Urology Business Growth

Friday, February 26, 2021 - 6:00am

Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of benign prostatic hyperplasia (BPH).

Key Points: 
  • Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of benign prostatic hyperplasia (BPH).
  • The company has identified and focused on gastroenterological endotherapy devices, urological devices and respiratory endotherapy devices as three priority therapeutic areas within TSD.
  • Olympus develops, manufactures and markets BPH treatment devices for TURP procedures such as resectoscopes and a wide variety of electrodes.
  • Medi-Tate is an Israeli medical device company dedicated to improving mens healthcare and quality of life via effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH).

Delays and Discord are Sinking COVAX, says AHF

Thursday, February 25, 2021 - 11:15pm

High-income countries now have a confirmed 4.2 billion doses, whereas low- and middle-income countries have only 670 million total .

Key Points: 
  • High-income countries now have a confirmed 4.2 billion doses, whereas low- and middle-income countries have only 670 million total .
  • Fewer than 100 doses had been administered in low-income countries, as of Feb. 8.
  • Developing countries are tired of waiting on COVAXits dysfunction has pushed many to seek their own deals with pharma companies.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210225006280/en/